Two-hundred and twenty-five House lawmakers April 18 urged the Centers for Medicare & Medicaid Services (CMS) to delay the April 21 release of the overall hospital quality star ratings in order “to provide the necessary time to more closely examine the star rating methodology, analyze its impact on different types of hospitals, and provide more transparent information regarding the calculation of the ratings to determine accuracy.”

The representatives wrote, “While we support the public reporting of provider quality data, we are concerned that the current Star Ratings system may not accurately take into account hospitals that treat patients with low socioeconomic status or multiple complex chronic conditions. We appreciate CMS’s recognition in previous rulemaking of the effects these patient populations have on Medicare Advantage and Part D plans and urge CMS to give similar consideration to the similar effects on the Hospital Compare Star Ratings system.”

The letter was spearheaded by Reps. Jim Renacci, R-Ohio, and Bill Pascrell, D-N.J.

Sixty senators sent a similar letter to CMS last week.

Related News Articles

Headline
About 80 percent of new HIV infections in the U.S. in 2016 were transmitted from the nearly 40 percent of people with HIV who either did not know they had HIV…
Headline
Historic flooding in parts of the Midwest caused a number of Nebraska hospitals to be inaccessible by ground transportation, the Nebraska Hospital Association…
Headline
The Senate Appropriations Committee’s Subcommittee on Labor, Health and Human Services, Education and Related Agencies today held a
Insights and Analysis
In this AHA Stat Blog, Institute for Diversity and Health Equity President and CEO Duane Reynolds shares some takeaways from the recent ACHE conference and…
Insights and Analysis
This week, as part of the South by Southwest (SXSW) festival’s Interactive Health and MedTech track, the American Hospital Association and hospital leaders…
Headline
A federal court has ordered a Texas-based company to stop producing compounded drug products intended to be sterile until the company complies with the Federal…